Beta Bionics (NASDAQ:BBNX) Price Target Raised to $16.00

Beta Bionics (NASDAQ:BBNX) had its price target hoisted by Robert W. Baird from $14.00 to $16.00 in a research report released on Tuesday, MarketBeat reports. Robert W. Baird currently has a neutral rating on the stock.

Several other research firms also recently weighed in on BBNX. William Blair assumed coverage on Beta Bionics in a report on Friday, August 21st. They issued a “market perform” rating for the company. UBS Group reissued a “buy” rating and set a $25.00 target price on shares of Beta Bionics in a research report on Tuesday. Bank of America reduced their price target on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a report on Monday, May 18th. Truist Financial upped their price target on shares of Beta Bionics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Leerink Partners increased their price objective on shares of Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.90.

Beta Bionics Stock Down 3.4%

Shares of NASDAQ BBNX opened at $21.43 on Tuesday. The business has a fifty day simple moving average of $17.56 and a two-hundred day simple moving average of $13.99. The firm has a market cap of $964.14 million, a PE ratio of -12.99 and a beta of 3.37. Beta Bionics has a twelve month low of $8.80 and a twelve month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The business had revenue of $32.01 million during the quarter. On average, research analysts expect that Beta Bionics will post -2.05 earnings per share for the current year.

Insider Buying and Selling

In other Beta Bionics news, insider Mark Hopman sold 30,779 shares of Beta Bionics stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $20.13, for a total value of $619,581.27. Following the transaction, the insider owned 56,479 shares in the company, valued at $1,136,922.27. The trade was a 35.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Russell sold 4,221 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $80,663.31. Following the completion of the transaction, the insider owned 169,628 shares of the company’s stock, valued at $3,241,591.08. This represents a 2.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 103,561 shares of company stock valued at $1,962,504. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Beta Bionics

Institutional investors have recently modified their holdings of the company. Eventide Asset Management LLC grew its position in shares of Beta Bionics by 0.8% in the 4th quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock worth $152,233,000 after buying an additional 37,476 shares during the last quarter. BlackRock Inc. bought a new position in shares of Beta Bionics during the 2nd quarter worth approximately $52,340,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Beta Bionics during the fourth quarter valued at approximately $40,437,000. Eversept Partners LP purchased a new stake in Beta Bionics during the fourth quarter valued at approximately $20,667,000. Finally, 12 West Capital Management LP acquired a new stake in Beta Bionics in the fourth quarter valued at approximately $17,520,000.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding the company’s diabetes-device portfolio. A full U.S. launch is planned for the first quarter of 2027, potentially creating a second commercial growth driver alongside the iLet Bionic Pancreas. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Beta Bionics completed a public offering that generated $172.5 million in gross proceeds, including the underwriters’ full option exercise. The capital could support Mint commercialization, manufacturing expansion, research and development, and working capital, strengthening the balance sheet ahead of the launch. Beta Bionics Announces Closing of $172.5 Million Public Offering
• Neutral Sentiment: Recent insider sales included 30,779 shares sold by Mark Hopman and 2,650 shares sold by Mike Mensinger under pre-arranged Rule 10b5-1 plans. The transactions may attract attention, although they do not necessarily indicate a change in management’s outlook.
• Negative Sentiment: The offering involved millions of new shares and pre-funded warrants priced at $17.25, creating substantial potential dilution for existing shareholders and likely contributing to near-term selling pressure.
• Negative Sentiment: Beta Bionics faces a securities class action covering investors who purchased shares during much of 2025 and early 2026. Allegations involve the company’s disclosures concerning an FDA Form 483, a subsequent warning letter, quality-management issues and unreported customer complaints. The claims remain allegations, but the litigation adds legal, reputational and regulatory uncertainty. BBNX Shareholder Alert
• Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the roughly $133.9 million consensus estimate, signaling slower near-term growth than analysts expected.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.